

## ENVOY® 500 GLUCOSE REAGENT KIT

## Product no. 55345

For in vitro diagnostic use

# CAUTION : Federal Law restricts this device to sale by or on the order of a licensed healthcare practitioner (Rx ONLY) Store this reagent at 2 to 8 °

INTENDED USE

Envoy® 500 Glucose Reagent is for the quantitative *in vitro* diagnostic determination of glucose in human serum and plasma on Envoy 500 Series Analysers. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabete mellitus, neonatal hypoglycemia and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

It is not intended for use in Point of Care settings.

## CLINICAL SIGNIFICANCE (1-3)

Glucose is the main source of energy for the human body. Glucose is converted either into glycogen to be stocked in the liver or into triglycerides to be stocked in fatty tissues. Glucose concentration in blood is regulated by several hormones, including two antagonists : insulin and glucagon. Quantification of glucose in blood is used to diagnose metabolic carbohydrates disorders such as diabetes, idiopathic hypoglycemia and pancreatic disease. The main physiological troubles are linked to hyperglycaemia (type I Diabetes mellitus and type II Diabetes mellitus). Type I diabetes mellitus is insulin-dependent, and appears mainly before 30 years old. Type II diabetes mellitus is non-insulin-dependent, and usually appears after 40 years old, but can occur earlier for obese people. Other diabetes have secondary origin, and appear after endocrinal or hepatic diseases.

#### METHODOLOGY (4,5)

Enzymatic determination of glucose according to the following reactions (Trinder reaction -End point):

Glucose + O<sub>2</sub>  $\xrightarrow{\text{Glucose oxidase}}$  Gluconic acid + H<sub>2</sub>O<sub>2</sub>

 $2H_2O_2$  + Phenol + 4-AAP  $\longrightarrow$  Quinoneimine +  $4H_2O$ 

4-AAP = 4-Aminoantipyrine

The red quinoneimine dye absorbs at 510 nm. The final absorbance at this wavelength is proportional to the concentration of glucose in the sample.

#### REAGENTS

#### COMPOSITION

Glucose Reagent contains 13.8 mmol/L Phosphate buffer, pH 7.4; 10 mmol/L Phenol; 0.3 mmol/L 4-Aminoantipyrine;  $\geq$  10,000 U/L Glucose oxidase (Aspergillus sp.);  $\geq$  700 U/L Peroxidase (horseradish); < 0.1% Sodium azide.

#### WARNINGS AND PRECAUTIONS

- This reagent is for professional in vitro diagnostic use only.

- Take normal precautions and adhere to good laboratory practice.

 Use clean or single use laboratory equipment only to avoid contaminations.

 The reagent R contains sodium azide, which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of these reagent always flush with copious amounts of water to prevent azide buildun

- Dispose of contents in accordance with all local, state and federal regulations.

- For more information, Safety Data Sheet (SDS) is available on request for professional user.

#### PREPARATION

Glucose Reagent is ready for use on the Envoy 500 Analyzer as packaged.

Store this reagent at 2 to 8 °C and protected from light. Do not freeze Unopened reagents are stable to the expiration dates on the bottle labels. The reagent is stable for 28 days onboard the Envoy 500 Analyzer.

## • SPECIMENS (1)

#### COLLECTION AND STORAGE

- Fresh unhemolyzed serum or lithium heparinized plasma is the preferred specimen. Do not analyze whole blood.

 Venipuncture should be performed prior to the administration of drugs.
 Of particular note, venipuncture performed during an acetaminophen overdose situation, when, N-acetyl-p-benzoquinone imine (NAPQI) an atypical metabolic breakdown product of acetaminophen, may be present, may lead to erroneously low glucose results. Venipuncture performed during or immediately after administration of N-acetylcysteine (NAC), a drug used to treat acetaminophen overdose, or Metamizole may lead to erroneously low glucose results.

 Samples must be separated from clot or cells promptly after collection to minimize loss of glucose through glycolysis (decrease of 5-7% in one hour in whole blood at room temperature).

- For best results, use only fresh specimens. Glucose in serum is stable for 8 hours at 25  $^\circ C$  or 72 hours at 2 to 8  $^\circ C.$ 

## PROCEDURE

#### MATERIALS PROVIDED

The Envoy 500 Glucose Reagent Kit includes the following components: 8 x 49.3 mL boats of Envoy 500 Glucose Reagent.

#### MATERIALS REQUIRED BUT NOT PROVIDED

- Envoy 500 Serum Calibrator (product no. 55111).
- Envoy 500 Serum Controls (product no. 55131).
- Normal saline.
- Analyzer specific consumables
- General Laboratory Equipment.

## REAGENT INSTALLATION AND USE

Program the instrument using the application parameters and programming instructions provided at the end of this Instructions For Use.

Refer to the Operator Manual for additional information on installing reagents and programming the analyzer, and running samples, calibrators and controls.

The Envoy 500 Glucose Reagent is ready to use as packaged.

Do not remove the caps from the bottles until you are ready to install the reagent on the analyzer. Before installing, mix the reagents by gently inverting the reagent boats several times. Record the installation date on the label and insert the unit into the designated position on the reagent tray. Let the reagent equilibrate on the instrument for at least 30 minutes before use.

## CALIBRATION

Calibrate the instrument after loading new reagent lot, after maintenance and whenever quality control results fall outside established limits. Under typical use conditions, calibration factors for this test are valid for 28 days. Refer to the Operator Manual for calibration procedures.

## QUALITY CONTROL

Quality control requirements should be established in accordance with local, state and/or federal regulations or accreditation requirements.

Assay at least two levels of serum control daily. Serum Controls for Envoy500 level 1 and level 2 may be used. Controls should also be assayed after performing a reagent blank, calibrating, maintaining the instrument and after loading a new reagent unit.

Controls may be assayed more frequently based on laboratory workflow and the discretion of the user.

.../..

ELITech Clinical Systems SAS Zone Industrielle 61500 SEES France

(855) 354-8324 - www.elitechgroup.com 27 Wellington Road Lincoln, Rhode Island 02865 - U.S.A.

For Technical questions, Please call or contact

(03/2016) FTEVY-GPSL-v3

CALCULATIONS	Uric acid:					
All calculations an To calculate the re	Methyl dopa:					
conventional units	(mg/aL) by U	.0555.	_		<u>L-Dopa</u> :	
PERFORMANC	E CHARAC	TERISTIC	S			
<b>MEASURING RANGE</b> Determined according to CLSI <sup>(6)</sup> EP6-A protocol, the measuring range is listed below. Samples that exceed the upper limit should be diluted 1:5 with NaCl 9 g/L solution (normal saline) and re-assayed. This extended measuring range was confirmed in a study where a high concentration of glucose was spiked into native serum samples. The recovery observed did not exceed the expected recovery by >±10%.					Tolazamide: Acetaminophen: - In very rare ca in particular IgM	
The «Re-run hype Results take the d	eractive» func	tion perforr count.	ns the dilutio	on automatically.	unreliable result	
Range	<ul> <li>Results may b NAC, NAPQI (a zole are signification)</li> </ul>					
Hyperactive	ault 20.0 to 400.0 mg/dL 1.11 to 22.20 mmol/L 2019 are signific peractive 400.0 to 2000.0 mg/dL 22.20 to 111.01 mmol/L - Other compol					
LIMIT OF DETEC (LOQ)	TION (LOD)	AND LIMIT	OF QUANT	IFICATION	• REFERENC	
Determined accord mmol/L) and LoQ i <b>EXPECTED VALU</b> Published glucose ranges only as gui ranges.	ing to CLSI <sup>(7)</sup> E s 10.0 mg/dL ( JES <sup>(1,3)</sup> reference rand des. Each lab	P17-A proto 0.56 mmol/l ges for adul oratory shou	bcol, the LoD i _). Its are listed l uld establish i	s 1.9 mg/dL (0.11 below. Use these its own reference	1. Sacks, D.B., mistry, 5 <sup>th</sup> Ed., E Philadelphia US 2. Dods, R.F., <i>L</i> sis, Correlation, (Mosby Inc. eds 3. Tietz, N.W., <u>Q</u>	
Reference Ran	ge Conve	ntional Units	s SI Unit	s	ders eds. Philad	
Serum/plasma	74 to 1	106 mg/dL	4.1 to :	5.9 mmol/L	4. Trinder, P., D oxidase with an	
PRECISION Determined accord Sample n	ling to CLSI <sup>(8)</sup> mean	EP5-A2 pro Within-r	tocol. run Total		(1969), <b>6</b> , 24. 5. Burrin, JM., F <u>Biochem</u> ., (1989) 6. Evaluation of ocedures: a Sta	
0,001 80	36.0	0.8	<u>CV (%)</u>		document EP6-	
Level 2 80	112.8	0.5	2.2		7. Protocols for Quantification	
Level 3 80	311.5	0.6	1.9		(2004), <b>24</b> (34).	
METHOD COMP/ A comparative s Analyzer and an method) on 101 protocol. The sample conce and 22.69 mmol/L The parameters o	<ol> <li>Evaluation of M ethods; Appridocument EP5- 9. Method Com Approved Guide EP9-A2 (2002), 10. Interference Second Edition.</li> <li>Berth, M. &amp;</li> </ol>					
Correlation coeffic Linear regression:	containing mon of literature. Act					
	/INTERFERI	NG SUBST	ANCES		12. Young, D. S	
- Do not report results outside of the usable range.					13. Young, D. S	
- The results of th	AACC Press, (1					

other diagnostic test results, clinical findings and the patient's medical history.

- Studies have been performed to determine the level of interference from different compounds according to CLSI(10) EP7-A2 protocol. Recovery is within ± 10% of initial value of glucose concentration of 36.0 mg/dL, 108.1 mg/dL and 400.0 mg/dL.

Unconjugated bilirubin:	No significant interference up to 6.0 mg/dL (103 umol/L).
Conjugated bilirubin:	No significant interference up to 5.9 mg/dL
Hemoglobin:	No significant interference up to 250 mg/dL .
Triglycerides:	No significant interference up to 895 mg/dL (10.11 mmol/L).
Ascorbic acid:	No significant interference up to 2.0 mg/dL (114 µmol/L).

No significant interference up to 20.0 mg/dL (1190 umol/L). No significant interference up to 0.8 mg/dL (37.9 µmol/L). Induces falsely low results at therapeutic concentrations. No significant interference up to 40.0 mg/dL (1.28 mmol/L).

No significant interference up to 30.0 mg/dL (1.98 mmol/L).

rare cases, monoclonal gammopathies (multiple myeloma), ular IgM type (Waldenstrom's macroglobulinemia) can cause ole results.(11

ts may be falsely low when the sample is taken while levels of APQI (a metabolite of acetaminophen (paracetamol)) or Metamisignificant.

compounds may interfere.(12,13)

## ERENCES

s, D.B., Carbohydrates. Tietz Fundamentals of Clinical Che-5th Ed., Burtis, C.A. & Ashwood, E.R. (W.B. Saunders eds. lphia USA), (2001), 427. R.F., Diabetes Mellitus. Clinical Chemistry : Theory, Analy-

- relation, 4th Ed., Kaplan, L.A, Pesce, A.J., Kazmierczak, S.C., Inc. eds St Louis USA), (2003), 580 and appendix.
- N.W., <u>Clinical guide to laboratory tests</u>, 3rd Ed., (W.B. Saunls. Philadelphia USA), (1995), 268.
- ter. P., Determination of alucose in blood using alucose

with an alternative oxygen acceptor. Ann. Clin. Biochem., 6.24.

in, JM., Price, C.P., Measurement of blood alucose, Ann. Clin, m., (1985), 22, 327.

Jation of the Linearity of the Measurement of Quantitative Pr es: a Statistical Approach; Approved Guideline. CLSI(NCCLS) ent EP6-A (2003), 23 (16).

cols for Determination of Limits of Detection and Limits of fication; Approved Guideline. CLSI (NCCLS) document EP17-A 24 (34).

uation of Precision Performance of Quantitative Measurement ds; Approved Guideline—Second Edition. CLSI (NCCLS) ent EP5-A2 (2004), 24 (25).

nod Comparison and Bias estimation Using Patient Samples; ed Guideline—Second Edition. CLSI (NCCLS) document (2002), 22 (19).

rference Testing in Clinical Chemistry ; Approved Guideline— Edition. CLSI (NCCLS) document EP7-A2 (2005), 25 (27). th, M. & Delanghe, J. Protein precipitation as a possible ant pitfall in the clinical chemistry analysis of blood samples ing monoclonal immunoglobulins: 2 case reports and a review ture, Acta Clin Belg., (2004), 59, 263.

ng, D. S., Effects of preanalytical variables on clinical laborats, 2<sup>nd</sup> Ed., AACC Press, (1997).

ng, D. S., Effects of drugs on clinical laboratory tests, 4th Ed., Press. (1995).

Envoy is a registered trademark of ELITech Group.

#### GLOSSARY OF SYMBOLS

CONT	Contents		Manufacturer	REF	Catalog No.
LOT	Batch Code		See instruction for use		Use by
OPENED	Date opened / Installation date	IVD	In vitro diagnostic device	1	Tempe- rature Limitation
STAB DAYS	Number of days onboard stability	R	Reagent		
<ul> <li>Modification from previous version</li> </ul>					

ENVOY® 500 GLUCOSE REAGENT KIT

## APPLICATION PARAMETERS

PRIMARY PARAMETERS		CH	CHECK PARAMETERS				
0.1.		0111		Rea	gent Limit (mABS)		200
GLU GLU				ve Acceptance (%)	100		
Bar-Code Active		ive P		RUN SERUM			
Code for Bar-Code 331				Test Limit (Conc)	400		
Test Methodology PAP				Low Test Limit (C	1.9		
Method End Po		End Po	id Point near		Initial ABS (mABS	N/A	
Kind of Process Linear		Linear			Final ABS (mABS	N/A	
1st Filter 510		510			Max ABS Delta (r	9999	
2nd Filter 700		700		Prozone Check		Inactive	
Reactio	on direction	Increas	ing		Normal Range	Min	Max
REAG	ENTS				Man	[Us	er defined]
Number of reagents		nts	1		Woman	[Us	er defined]
Reagent 1 Volume µL		300 Inactive		Child	[Us	er defined]	
Concentrated				Re-run hyperactiv	e la la	Active	
Reagent 2 Volume µL		N/A		Re-run pathologic	Inactive		
C	oncentrated		Inactive	DE.			
SAMP	PLE	Serum	Urine	NL.	Test Limit (Conc)		N/A
Ni	ame	Glucose	N/A		Low Test Limit (C	onc)	N/A
Sa	ample µL	3	N/A		Initial ABS (mABS	3)	N/A
Pr	re-Dilution 1:	1	N/A		Final ABS (mABS	5)	N/A
P P	ost-Dilution 1:	5	N/A		Max ABS Delta (r	nABS)	N/A
TIMES	6				Prozone Check	11/12/07	Inactive
Sa	ample Starter		Inactive		Normal Range	Min	Max
D	elay Time		0		Man	11111	[] [sor defined]
Reading Time		60		Woman		[User defined]	
Reagent 1 Incubation Time		420		Child		[User defined]	
Reagent 2 Incubation Time		N/A		Po run hyporactive			
							Inactive
					INC-I ULI DALI DIDUL	ai	mactive

1<sup>#</sup> Unit Serum ma/dL Inactive 2<sup>nd</sup> Unit Serum 1<sup>st</sup> Unit Urine N/A 2<sup>nd</sup> Unit Urine Inactive Dynamic Blank Inactive Needle washes [From Settings Table] Cuvette washes [From Settings Table] Special Wash [From Settings Table] Instrumental Factor 1.000 Shift 0.000 Every Day Reagent Blank Decimals 1 STANDARD PARAMETERS [Determined by calibration] Factor Minimum 200 Maximum 500 Number of Samples 10 Max Var. (%) Timed re-run Inactive N. replicates 3 Reagents ABS [Determined by Envoy] Pos. [From Settings Table] Conc. [From calibrator labeling] ABS [Determined by Envov] % from last calibration 100

SECONDARY PARAMETERS

## PROGRAMMING INSTRUCTIONS

Detailed instructions for programming reagent parameters are provided in the Envoy 500 Operator Manual and Envoy500 Settings Table.

If the Envoy 500 Chemistry System is not pre-programmed, a Glucose code must first be added before the parameters can be entered. On the menu bar, select «Test → Test Directory.» A new window will open up listing all the codes for the tests that are installed on the instrument. Click on the «New Code» button, type «GLU» into the Code field and select «Save.»

To program the application parameters, check the box next to the code for the GLU test, and select the «Parameters» button located at the bottom of the window. To program standard information, click the «Standards» button located at the bottom of the window

ELITech Clinical Systems SAS Zone Industrielle 61500 SEES France

For Technical questions, Please call or contact (855) 354-8324 - www.elitechgroup.com 27 Wellington Road Lincoln, Rhode Island 02865 - U.S.A.

(03/2016) FTEVY-GPSI-v3 ELITech Clinical Systems SAS Zone Industrielle 61500 SEES France

For Technical questions, Please call or contact (855) 354-8324 - www.elitechgroup.com 27 Wellington Road Lincoln, Rhode Island 02865 - U.S.A.

